| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Karen G. Hirsch | Stanford University | NIH (has grantfunding from the NIH to study post–cardiac arrest brain injury)† | None | None | None | None | None | None |
| Romergryko G. Geocadin | Johns Hopkins University School of Medicine | NIH (grants to his institution for research)† | None | None | Medicolegal expert consultant* | None | None | Johns Hopkins University (professor)† |
| Benjamin S. Abella | University of Pennsylvania | None | None | Becton Dickinson†; Zoll†; Stryker* | None | Neuroptics* | Becton Dickinson†; Zoll† | None |
| Edilberto Amorim | University of California, San Francisco–Weill Institute for Neurosciences | AHA (career development award [CDA and AMFDP])†; NIH (career development award [K23])†; Zoll Foundation†; Hellman Foundation†; Regents of the University of California†; Cures Within Reach†; Cure Epilepsy† | None | None | None | None | None | None |
| Mary Kay Bader | Providence Mission Hospital Nursing Center of Excellence/Critical Care Services | None | None | Ceribell†; Neuroptics*; BD* | None | Neuroptics* | None | None |
| Jeffrey F. Barletta | Midwestern University | None | Society of Critical Care Medicine (He is an elected member of SCCM Council)* | None | None | None | Wolters Kluwer* | None |
| Katherine Berg | Beth Israel Deaconess Medical Center | None | None | None | None | None | AHA/ILCOR† | None |
| Clifton W. Callaway | University of Pittsburgh | None | None | None | None | None | None | None |
| Hans Friberg | Skane University Hospital (Sweden) | None | None | None | None | None | None | None |
| Emily J. Gilmore | Yale University School of Medicine | None | None | None | None | None | carpl.ai†; AAN* | None |
| David M. Greer | Boston University School of Medicine | None | None | None | None | None | None | None |
| Karl B. Kern | Sarver Heart Center, University of Arizona | None | None | None | None | None | None | None |
| Sarah Livesay | Rush University College of Nursing | None | None | None | Baptist Health South Florida*; Scott and Patton, PC† | Stroke Challenges, LLC* | None | None |
| Teresa L. May | Maine Medical Center | None | None | None | None | None | None | None |
| Robert W. Neumar | University of Michigan | NIH†; AHA†; Laerdal Foundation* | None | None | None | None | None | None |
| Jerry P. Nolan | Warwick Medical School, University of Warwick; Royal United Hospital (United Kingdom) | NIHR (grants for PARAMEDIC-3 and AIRWAYS-3 trials)* | None | None | None | None | None | None |
| Mauro Oddo | CHUV-Lausanne University Hospital (Switzerland) | None | None | None | None | None | None | None |
| Mary Ann Peberdy | Virginia Commonwealth University | None | None | None | None | None | None | None |
| Samuel M. Poloyac | University of Texas at Austin | None | None | None | None | None | None | None |
| David Seder | Maine Medical Center | NIGMS (PI of Adenosinergic Signaling in the Immunoinflammatory Response After Cardiac Arrest under NIGMS 1P20GM139745-01 [5491])† | None | None | None | None | None | None |
| Fabio Silvio Taccone | Hopital Universitaire de Bruxelles (Belgium) | None | None | None | None | None | NEUROPTICS*; NIHON KHODEN* | None |
| Anezi Uzendu | St. Luke’s Mid America Heart Institute | None | None | None | None | None | None | None |
| Brian Walsh | University of Texas Medical Branch School of Health Sciences | Sentec (IIR grant for EIT)† | None | Medtronic* | Expert witness* | FluidIQ† | Medtronic* | UTMB (associate professor)† |
| Janice L. Zimmerman | The Methodist Hospital Physician Organization | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition
*Modest
†Significant